Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation
Zusammenhang zwischen GLP-1-Rezeptoragonisten und Demenzrisiko bei älteren Erwachsenen mit Typ-2-Diabetes: Target-Trial-Emulation
Diabetes, Obesity and Metabolism · 2026-03 · 28 (3) · 1984-1996
DOI: 10.1111/dom.70384 ↗Auf einen Blick
GLP-1-Rezeptoragonisten waren bei älteren Erwachsenen mit Typ-2-Diabetes mit einem niedrigeren Demenzrisiko als DPP4-Inhibitoren verbunden, aber mit einem höheren Risiko als SGLT2-Inhibitoren.
Fragestellung
Ist der Beginn einer Therapie mit GLP-1-Rezeptoragonisten bei älteren Erwachsenen mit Typ-2-Diabetes mit einer geringeren Inzidenz von Demenz verbunden als DPP4-Inhibitoren oder SGLT2-Inhibitoren?
Methode
Retrospektive Kohortenstudie als Target-Trial-Emulation mit elektronischen Gesundheitsdaten des University of Pennsylvania Health System (2019–2024) und externer Validierung in TriNetX; Propensity-Score-Matching 1:1; Cox-Modelle.
Ergebnisse
GLP-1-RA vs. DPP4i: 109 vs. 148 Ereignisse; HR 0,76 (95 %-KI 0,59–0,97). GLP-1-RA vs. SGLT2i: 127 vs. 64 Ereignisse; HR 1,53 (95 %-KI 1,13–2,07).
Schlussfolgerung der Autor:innen
In dieser großen Real-World-Kohorte waren GLP-1-Rezeptoragonisten mit geringerem Demenzrisiko als DPP4i, aber höherem Risiko als SGLT2i verbunden. Prospektive, biomarkerinformierte Studien seien nötig.
Kernaussagen
- GLP-1-RA vs. DPP4i: HR 0,76 (95 %-KI 0,59–0,97)
- GLP-1-RA vs. SGLT2i: HR 1,53 (95 %-KI 1,13–2,07)
- Externe Validierung bestätigte den Vergleich mit DPP4i, nicht mit SGLT2i
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 22.12.2025. Verfasst von Ting Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dementia, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIDDK NIH HHS, NIA NIH HHS.
Themen: Diabetes mellitus, Gerontologische Pflege, Demenz
Abstract (Originalsprache)
Aim
Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults with T2D. Materials and methods We conducted a retrospective cohort study emulating a target trial using electronic health records from the University of Pennsylvania Health System (2019–2024), with external validation in the TriNetX U.S. Collaborative Network. Adults aged ≥50 with T2D, no prior dementia, and no GLP‐1 RA, DPP4i, or SGLT2i use in the previous year were eligible. New GLP‐1 RA users were propensity‐score matched (1:1) to DPP4i users ( n = 6677 pairs) and SGLT2i users ( n = 8434 pairs). The outcome was incident dementia, defined by ICD‐10‐CM codes. Cox proportional hazards models estimated hazard ratios (HRs), with multiple sensitivity and subgroup analyses performed.
Results
Over a median follow‐up of 3.0 years (GLP‐1 RA vs. DPP4i) and 2.4 years (GLP‐1 RA vs. SGLT2i), GLP‐1 RA use was associated with a lower dementia risk versus DPP4is (109 vs. 148 events; HR 0.76, 95% CI 0.59–0.97), but a higher risk versus SGLT2is (127 vs. 64 events; HR 1.53, 95% CI 1.13–2.07). Findings were consistent across sensitivity and subgroup analyses. External validation confirmed reduced dementia risk versus DPP4is but not versus SGLT2is.
Conclusions
In this large real‐world cohort, GLP‐1 RAs were associated with lower dementia risk than DPP4is but higher risk than SGLT2is. Prospective, biomarker‐informed studies are needed to clarify mechanisms and inform treatment choices in older adults with T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Pfizer, New York City, New York, USA.
- Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of General Internal Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Ting Zhou, Huilin Tang, Yong Chen
Förderung
- NIH HHS
- NIDDK NIH HHS
- NIA NIH HHS
- NLM NIH HHS
- NIMH NIH HHS
- NIAID NIH HHS
- NCATS NIH HHS
- NEI NIH HHS
Zitieren
APA
Zhou, T., Tang, H., Zhang, B., Zhang, D., Lu, Y., Li, L., Chen, J., Chen, Y., Asch, D. A., & Chen, Y. (2026). Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation. Diabetes, Obesity and Metabolism, 28(3), 1984-1996. https://doi.org/10.1111/dom.70384
Vancouver
Zhou T, Tang H, Zhang B, Zhang D, Lu Y, Li L, et al. Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation. Diabetes, Obesity and Metabolism. 2026;28(3):1984-1996. doi:10.1111/dom.70384
BibTeX
@article{Zhou2026,
author = {Zhou, Ting and Tang, Huilin and Zhang, Bingyu and Zhang, Dazheng and Lu, Yiwen and Li, Lu and Chen, Jiajie and Chen, Yong and Asch, David A and Chen, Yong},
title = {Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {3},
pages = {1984--1996},
doi = {10.1111/dom.70384}
}
EUVIMED